Anavex Makes Interim CEO Terrie Kellmeyer Permanent And Adds Her To A Five-Seat Board

The board dropped the interim label, kept her $500,000 base salary and shrank from six seats to five.

Share
Anavex Makes Interim CEO Terrie Kellmeyer Permanent And Adds Her To A Five-Seat Board

Anavex Life Sciences, a clinical-stage biopharmaceutical company, appointed Terrie Kellmeyer permanent President and CEO and a director, according to an 8-K filed Tuesday. Her board made the move effective November 1, after she had served as interim CEO since May 4, 2026.

Pay stays put, review coming

Kellmeyer, 59, keeps an annual base salary of $500,000, and her annual bonus continues to be anticipated at 30% of base. The board plans a near-term review of her employment agreement and will get advice from an independent compensation consultant on her current pay.

At the same time, the board cut its size from six seats to five, with Kellmeyer taking a seat. It has started a search for an additional independent director to fill the fifth.

Board praises her FDA work

Board member Peter Donhauser, D.O., said in the company's press release that the decision reflects "unequivocal support for her strategy and her plans to build a top-notch management team."

The company said that under her interim leadership it completed key clinical pharmacology studies, won FDA clearance of its investigational new drug application in Fragile X syndrome, and advanced its planned late-stage Rett syndrome program.

Kellmeyer said her priorities are "disciplined execution of our clinical plans" and generating high-quality data to support regulatory decisions.

A returning insider

Anavex is still testing its drug candidates and sells no approved products. It is developing blarcamesine, also called ANAVEX 2-73, in Alzheimer's disease, Rett syndrome and Fragile X syndrome.

Kellmeyer was Anavex's senior vice president of clinical development from November 2023 to May 2025, then stayed on as a senior advisor until she became interim CEO. From May 2025 to May 2026 she was executive vice president of regulatory affairs at Aardvark Therapeutics, where she remains a strategic advisor. The filing credits her with more than 30 years in the pharmaceutical industry.

Anavex shares traded at $1.16 in Tuesday trading, about 3% below the prior close of $1.19.

The board's near-term review of Kellmeyer's employment agreement and its hunt for a fifth, independent director are the next moves on the governance calendar.

Sources

More on Anavex Life Sciences

All Anavex Life Sciences (AVXL) coverage →